KING OF PRUSSIA, PA — XyloCor Therapeutics Inc. announced the appointment of John Tucker as president and chief executive officer, effective immediately.
Tucker succeeds the company’s interim leadership and will also join XyloCor’s board of directors, the company said.
The clinical-stage biotechnology company said Tucker brings more than 20 years of leadership experience in the life sciences and biotechnology industries.
Tucker previously served as chief executive officer of scPharmaceuticals and earlier held the same role at Alcresta Therapeutics.
His experience includes work on clinical development programs, fundraising efforts, regulatory approvals and commercialization initiatives, according to the company.
“XyloCor is at a pivotal moment in its evolution,” Tucker said. “With a promising pipeline and a deeply committed team, we are well positioned to transform the treatment landscape for patients with cardiovascular disease.”
Glenn Batchelder, chairman of XyloCor’s board of directors, said the appointment followed an executive search conducted by the board.
“John is a dynamic and visionary leader with the operational expertise and strategic insight needed to guide XyloCor through its next phase of development,” Batchelder said.
XyloCor is a clinical-stage biotechnology company developing gene therapies aimed at treating cardiovascular disease.
The company’s lead product candidate, XC001, is being studied for patients with coronary artery disease and refractory angina who have limited treatment options, according to the company.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.